Switch theme
Sign up to access all valuation multiples
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
2014
281
LTM Revenue $74.0M
LTM EBITDA -$43.2M
$447M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CeriBell has a last 12-month revenue (LTM) of $74.0M and a last 12-month EBITDA of -$43.2M.
In the most recent fiscal year, CeriBell achieved revenue of $65.4M and an EBITDA of -$37.3M.
CeriBell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CeriBell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $74.0M | XXX | $65.4M | XXX | XXX | XXX |
| Gross Profit | $63.5M | XXX | $56.8M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | -$43.2M | XXX | -$37.3M | XXX | XXX | XXX |
| EBITDA Margin | -58% | XXX | -57% | XXX | XXX | XXX |
| EBIT | -$47.3M | XXX | -$39.7M | XXX | XXX | XXX |
| EBIT Margin | -64% | XXX | -61% | XXX | XXX | XXX |
| Net Profit | -$46.9M | XXX | -$40.5M | XXX | XXX | XXX |
| Net Margin | -63% | XXX | -62% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CeriBell's stock price is $17.
CeriBell has current market cap of $608M, and EV of $447M.
See CeriBell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $447M | $608M | XXX | XXX | XXX | XXX | $-2.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CeriBell has market cap of $608M and EV of $447M.
CeriBell's trades at 6.8x EV/Revenue multiple, and -12.0x EV/EBITDA.
Equity research analysts estimate CeriBell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CeriBell has a P/E ratio of -13.0x.
See valuation multiples for CeriBell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $608M | XXX | $608M | XXX | XXX | XXX |
| EV (current) | $447M | XXX | $447M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | -10.3x | XXX | -12.0x | XXX | XXX | XXX |
| EV/EBIT | -9.4x | XXX | -11.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.0x | XXX | -15.0x | XXX | XXX | XXX |
| EV/FCF | -10.9x | XXX | -12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCeriBell's last 12 month revenue growth is 30%
CeriBell's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
CeriBell's rule of 40 is -28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CeriBell's rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CeriBell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | -58% | XXX | -57% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -28% | XXX | -27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 147% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CeriBell acquired XXX companies to date.
Last acquisition by CeriBell was XXXXXXXX, XXXXX XXXXX XXXXXX . CeriBell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CeriBell founded? | CeriBell was founded in 2014. |
| Where is CeriBell headquartered? | CeriBell is headquartered in United States of America. |
| How many employees does CeriBell have? | As of today, CeriBell has 281 employees. |
| Who is the CEO of CeriBell? | CeriBell's CEO is Dr. Xingjuan Chao, PhD. |
| Is CeriBell publicy listed? | Yes, CeriBell is a public company listed on NAS. |
| What is the stock symbol of CeriBell? | CeriBell trades under CBLL ticker. |
| When did CeriBell go public? | CeriBell went public in 2024. |
| Who are competitors of CeriBell? | Similar companies to CeriBell include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of CeriBell? | CeriBell's current market cap is $608M |
| What is the current revenue of CeriBell? | CeriBell's last 12 months revenue is $74.0M. |
| What is the current revenue growth of CeriBell? | CeriBell revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of CeriBell? | Current revenue multiple of CeriBell is 6.0x. |
| Is CeriBell profitable? | Yes, CeriBell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CeriBell? | CeriBell's last 12 months EBITDA is -$43.2M. |
| What is CeriBell's EBITDA margin? | CeriBell's last 12 months EBITDA margin is -58%. |
| What is the current EV/EBITDA multiple of CeriBell? | Current EBITDA multiple of CeriBell is -10.3x. |
| What is the current FCF of CeriBell? | CeriBell's last 12 months FCF is -$41.0M. |
| What is CeriBell's FCF margin? | CeriBell's last 12 months FCF margin is -55%. |
| What is the current EV/FCF multiple of CeriBell? | Current FCF multiple of CeriBell is -10.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
